Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review

Autor: Reeti Joshi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Yujin Park, Prashanth Sunkureddi

Publikováno v: Drugs - Real World Outcomes, Vol 6, Iss 1, Pp 1-9 (2019)

Abstract Objectives To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice. Methods This descriptive analysis of data

Externí odkaz: https://doaj.org/article/62e387acb27e4aecb804402811657616

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

Autor: Peter Hur, Reeti Joshi, Jipan Xie, Dominick Latremouille-Viau, Prashanth Sunkureddi, Mark K. Meiselbach

Publikováno v: Rheumatology and Therapy
Rheumatology and Therapy, Vol 6, Iss 1, Pp 89-100 (2019)

Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::935332b4ad10c410b936355fb00b0dd6
http://europepmc.org/articles/PMC6393268

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis

Autor: Samir Benosman, Dawn Gibson, Stephen Doogan, John Heid, Prashanth Sunkureddi, Yujin Park

Publikováno v: Advances in Therapy

Introduction Online communities contain a wealth of information containing unsolicited patient experiences that may go beyond what is captured by guided surveys or patient-reported outcome (PRO) instruments used in clinical settings. This study descr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff931349bf9668131e429860155fd5f
http://europepmc.org/articles/PMC5859700

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Autor: Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark Genovese, Khalid Ahmed, Jeffrey Alper, Nichol Barkham, Ralph E. Bennett, Francisco Javier Blanco García, Ricardo Blanco Alonso, Howard B. Blumstein, Michael S. Brooks, Gerd-Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der-Yuan Chen, Melvin A. Churchill, Christine E. Codding, Peter M.G. Deane, Jose Del Giudice, Atul A. Deodhar, Rajat K. Dhar, Eva Dokoupilova, Rita M. Egan, Andrea Everding, Eva Galíndez, David H. Goddard, Alice Gottlieb, Philippe Goupille, Robert M. Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu-Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan J. Kivitz, Steven J. Klein, Mariusz P. Korkosz, Roshan Kotha, Joel M. Kremer, Cummins Lue, José Luis Marenco de la Fuente, Helena Marzo-Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama C. Nandagudi, Antonio Fernández-Nebro, Clark M. Neuwelt, Ana Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria E. Rell-Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David H. Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen-Fang Tsai, Anthony M. Turkiewicz, Leonore Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielinska

Publikováno v: Lancet (London, England). 389(10086)

Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e86bed9c822e2b158c34f88e2aa99b8
https://pubmed.ncbi.nlm.nih.gov/28592895

Isolated elevation of IgA anti-β2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients

Autor: Emilio B. Gonzalez, S. Kumar, S. Najam, Elizabeth Papalardo, Prashanth Sunkureddi, Silvia S. Pierangeli

Publikováno v: Lupus. 18:1011-1014

Current diagnostic classification criteria recommend elevated titres of anti-cardiolipin (aCL) and/or anti-β2GPI antibody by ELISA IgG or IgM and/or lupus anticoagulant (LA) to confirm antiphospholipid syndrome (APS). Although IgA aPL antibodies hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::805c0591274fa0ddad9daec763e9a7dd
https://doi.org/10.1177/0961203309103048